How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,722 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. (PubMed)

Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Mycosis fungoides (MF) is a primary cutaneous T-cell lymphoma with unfavourable prognosis for patients with advanced stages of the disease. Refractory disease and advanced-stage disease require systemic therapy. We report on a rare case of an atypical predominantly CD8+ folliculotropic MF, a subtype of MF with poorer prognosis, in a 59-year-old

2018 British Journal of Dermatology

82. New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia. (PubMed)

New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia. 30561000 2019 02 05 1365-2133 2018 Dec 18 The British journal of dermatology Br. J. Dermatol. New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia. 10.1111/bjd.17533 Pileri A A https://orcid.org/0000-0002-1025-7171 Dermatology Unit, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Via Massarenti 1

2018 British Journal of Dermatology

83. Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Patient Version

Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Patient Version Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer (...) Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search term Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: March 28, 2019. This PDQ cancer information summary has current information about the treatment of mycosis fungoides (including Sézary Syndrome). It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care

2016 PDQ - NCI's Comprehensive Cancer Database

84. Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Health Professional Version

Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Health Professional Version Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ (...) Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search term Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) Health Professional Version PDQ Adult Treatment Editorial Board . Published online: July 5, 2018. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of mycosis fungoides (including Sézary Syndrome). It is intended as a resource to inform and assist clinicians who care

2016 PDQ - NCI's Comprehensive Cancer Database

85. Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome

Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care

2017 Clinical Trials

86. Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides

Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03454945 Recruitment Status : Recruiting First Posted : March 6, 2018 Last Update Posted : August

2017 Clinical Trials

87. Maintenance phase in PUVA phototherapy of early stage mycosis fungoides. A critically appraised topic. (PubMed)

Maintenance phase in PUVA phototherapy of early stage mycosis fungoides. A critically appraised topic. A 65-year-old patient affected by mycosis fungoides (MF) stage IB achieved complete remission (CR) after a cycle of PUVA phototherapy. The U.S. Cutaneous Lymphoma Consortium (USCLC) guidelines suggest that the patient should be kept in the maintenance phase, defined as a 'period of gradual decrease of frequency of UVL [ultraviolet light] while in clinical remission before discontinuation (...) PUVA phototherapy. Embase, PubMed and TRIP databases were searched for 'mycosis fungoides' AND [('photochemotherapy' OR 'puva') OR 'psoralen'] in June 2016. Three articles matched our inclusion criteria and are discussed in this CAT. In this field of research the literature is poor and the reported level of evidence is low. Only one of the studies was conducted prospectively, and none were randomized. No significant difference in terms of reduction in relapse rate or increase in RFI in patients who

2017 British Journal of Dermatology

88. Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study. (PubMed)

Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study. Toll-like receptors (TLRs) have been implicated in various dermatological diseases. TLR agonists have the capacity to potently activate the innate immune cells of patients with advanced, refractory, cutaneous T-cell lymphoma (CTCL).To detect TLR7 gene expression in mycosis fungoides (MF) (a neoplastic skin condition) and to compare it with psoriasis (an inflammatory skin condition) in an attempt

Full Text available with Trip Pro

2017 Clinical & Experimental Dermatology

89. Telangiectatic Mycosis Fungoides: A New Clinicopathological Presentation Mimicking Acquired Naevoid Telangiectasia. (PubMed)

Telangiectatic Mycosis Fungoides: A New Clinicopathological Presentation Mimicking Acquired Naevoid Telangiectasia. 28093597 2018 04 17 2018 04 17 1651-2057 97 5 2017 05 08 Acta dermato-venereologica Acta Derm. Venereol. Telangiectatic Mycosis Fungoides: A New Clinicopathological Presentation Mimicking Acquired Naevoid Telangiectasia. 651-652 10.2340/00015555-2613 García-Colmenero Lidia L Department of Dermatology, Hospital del Mar. Parc de Salut Mar., Passeig Marítim 25-29, ES-08003 Barcelona (...) , Spain. lidia.garcia.colmenero@gmail.com. Curto-Barredo Laia L Gómez-Martin Ignacio I Gallardo Fernando F Pujol Ramon M RM eng Case Reports Journal Article Sweden Acta Derm Venereol 0370310 0001-5555 IM Diagnosis, Differential Humans Male Middle Aged Mycosis Fungoides complications diagnosis pathology Skin Neoplasms complications diagnosis pathology Telangiectasis complications diagnosis 2017 1 18 6 0 2018 4 18 6 0 2017 1 18 6 0 ppublish 28093597 10.2340/00015555-2613

Full Text available with Trip Pro

2017 Acta Dermato-Venereologica

90. Mycosis fungoides occurring at the site of previous herpes zoster eruption. (PubMed)

Mycosis fungoides occurring at the site of previous herpes zoster eruption. Numerous clinicopathological variants of mycosis fungoides have been described in the literature. Dermatomal or zosteriform mycosis fungoides is one reported variant but a clear aetiology has never been documented. We report a case of mycosis fungoides proved by biopsy and immunohistochemistry that developed in a 55-year-old man at the site of previous herpes zoster eruption. We also present a review of the relevant (...) literature to add to the understanding of rare variants of mycosis fungoides and aid in the clinical recognition of zosteriform mycosis fungoides.© 2017 The Australasian College of Dermatologists.

2017 Australasian Journal of Dermatology

91. Combination of low-dose total skin electron beam therapy and subsequent localized skin electron beam therapy as a therapeutic option for advanced-stage mycosis fungoides. (PubMed)

Combination of low-dose total skin electron beam therapy and subsequent localized skin electron beam therapy as a therapeutic option for advanced-stage mycosis fungoides. Electron beam therapy (EBT) is an established treatment for mycosis fungoides (MF), but evidence for the use of EBT in advanced cutaneous conditions is limited, and optimal scheduling of the regimen for such conditions remains unclear. We report the case of a 44-year-old woman diagnosed with MF with widespread cutaneous

2017 Clinical & Experimental Dermatology

92. Expression of FK506-binding protein 51 (FKBP51) in Mycosis Fungoides. (PubMed)

Expression of FK506-binding protein 51 (FKBP51) in Mycosis Fungoides. Mycosis fungoides (MF) is the major subtype of cutaneous T-cell lymphomas (CTCL). It usually has a prolonged indolent clinical course with a minority of cases acquiring a more aggressive biological profile and resistance to conventional therapies, partially attributed to the persistent activation of nuclear factor-kappa B (NF-κB) pathway. In the last decade, several papers suggested an important role for the FK506-binding

2017 Journal of the European Academy of Dermatology and Venereology

93. No Viral Transcripts Associated with Folliculotropic Mycosis Fungoides Using a High Throughput Sequencing Approach. (PubMed)

No Viral Transcripts Associated with Folliculotropic Mycosis Fungoides Using a High Throughput Sequencing Approach. is missing (Short communication).

Full Text available with Trip Pro

2017 Acta Dermato-Venereologica

94. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. (PubMed)

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Advanced-stage mycosis fungoides (MF)/Sézary syndrome (SS) patients are weighted by an unfavorable prognosis and share an unmet clinical need of effective treatments. International guidelines are available detailing treatment options for the different stages but without recommending treatments in any particular order due

Full Text available with Trip Pro

2017 Annals of Oncology

95. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. (PubMed)

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. In order to provide a common standard for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) published in 2006 its consensus recommendations for the stage-adapted selection of management options for these neoplasms. Since

Full Text available with Trip Pro

2017 European Journal of Cancer

96. Early stage mycosis fungoides screening investigations: a retrospective analysis of 440 cases. (PubMed)

Early stage mycosis fungoides screening investigations: a retrospective analysis of 440 cases. 29220538 2018 06 07 1468-3083 32 6 2018 Jun Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Early-stage mycosis fungoides screening investigations: a retrospective analysis of 440 cases. e217-e218 10.1111/jdv.14735 Bawazir M A MA Division of Dermatology, Department of Medicine, University of Toronto, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada

2017 Journal of the European Academy of Dermatology and Venereology

97. Folliculotropism Does Not Affect Overall Survival in Mycosis Fungoides: Results from a Single-Center Cohort and Meta-Analysis. (PubMed)

Folliculotropism Does Not Affect Overall Survival in Mycosis Fungoides: Results from a Single-Center Cohort and Meta-Analysis. Folliculotropic mycosis fungoides (FMF) is a distinct subtype of mycosis fungoides (MF) with unique clinicopathological features. The medical literature suggests that FMF has a more aggressive course and worse survival than classic MF. Previous studies do not use standardized treatment, and no studies have reported an association between treatment response and overall

Full Text available with Trip Pro

2017 Dermatology (Basel, Switzerland)

98. Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. (PubMed)

Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. Immunodeficiency (ID) correlates with worse outcomes and decreased immune checkpoint molecule expression in melanoma. The impact of ID in mycosis fungoides (MF) is unknown.Our goal was to evaluate the impact of ID in MF.We conducted a case-control study of 17 patients with MF and ID versus age-, stage-, and race-matched

2017 Journal of American Academy of Dermatology

99. Trichoscopic spectrum of folliculotropic mycosis fungoides. (PubMed)

Trichoscopic spectrum of folliculotropic mycosis fungoides. 28924975 2018 03 14 1468-3083 32 3 2018 Mar Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Trichoscopic spectrum of folliculotropic mycosis fungoides. e107-e108 10.1111/jdv.14596 Sławińska M M Department of Dermatology, Venerology and Allergology, Medical University of Gdańsk, Gdańsk, Poland. Sobjanek M M Department of Dermatology, Venerology and Allergology, Medical University

2017 Journal of the European Academy of Dermatology and Venereology

100. Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. (PubMed)

Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Mycosis fungoides (MF) is the most frequent form of cutaneous T-cell lymphoma. The disease often takes an indolent course, but in approximately one-third of the patients, the disease progresses to an aggressive malignancy with a poor prognosis. At the time of diagnosis, it is impossible to predict which patients develop severe disease and are in need of aggressive treatment

2017 Blood

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>